Total Payments
$10,692
2024 Payments
$5,164
Companies
9
Transactions
17
Medicare Patients
2,259
Medicare Billing
$106,806
Payment Breakdown by Category
Other$5,125 (47.9%)
Consulting$2,400 (22.4%)
Research$1,664 (15.6%)
Travel$881.63 (8.2%)
Food & Beverage$620.99 (5.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,125 | 1 | 47.9% |
| Consulting Fee | $2,400 | 1 | 22.4% |
| Unspecified | $1,664 | 3 | 15.6% |
| Travel and Lodging | $881.63 | 3 | 8.2% |
| Food and Beverage | $620.99 | 9 | 5.8% |
Payments by Type
General
$9,028
14 transactions
Research
$1,664
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $5,125 | 1 | $0 (2024) |
| Eli Lilly and Company | $2,771 | 8 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $2,400 | 1 | $0 (2021) |
| Celgene Corporation | $136.87 | 1 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $116.12 | 1 | $0 (2023) |
| Lilly USA, LLC | $64.00 | 2 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $39.08 | 1 | $0 (2024) |
| DUSA Pharmaceuticals, Inc. | $26.33 | 1 | $0 (2018) |
| Janssen Research & Development, LLC | $13.35 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,164 | 2 | GENZYME CORPORATION ($5,125) |
| 2023 | $143.29 | 2 | Boehringer Ingelheim Pharmaceuticals, Inc. ($116.12) |
| 2022 | $59.83 | 2 | Lilly USA, LLC ($36.83) |
| 2021 | $2,400 | 1 | Novartis Pharmaceuticals Corporation ($2,400) |
| 2020 | $139.09 | 1 | Eli Lilly and Company ($139.09) |
| 2019 | $1,652 | 3 | Eli Lilly and Company ($1,502) |
| 2018 | $1,133 | 6 | Eli Lilly and Company ($1,107) |
All Payment Transactions
17 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,125.00 | General |
| Category: Immunology | ||||||
| 03/09/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $39.08 | General |
| Category: Immunology | ||||||
| 10/27/2023 | Lilly USA, LLC | OLUMIANT (Drug) | Food and Beverage | In-kind items and services | $27.17 | General |
| Category: Immunology | ||||||
| 07/29/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $116.12 | General |
| 05/09/2022 | Eli Lilly and Company | — | — | In-kind items and services | $23.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | ||||||
| 03/26/2022 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $36.83 | General |
| Category: Immunology | ||||||
| 10/16/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: IMMUNOLOGY | ||||||
| 08/10/2020 | Eli Lilly and Company | — | — | In-kind items and services | $139.09 | Research |
| Study: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | ||||||
| 05/09/2019 | Janssen Research & Development, LLC | Tremfya (Drug) | Food and Beverage | In-kind items and services | $13.35 | General |
| Category: Immunology | ||||||
| 03/01/2019 | Celgene Corporation | Otezla (Drug) | Food and Beverage | In-kind items and services | $136.87 | General |
| Category: Dermatology | ||||||
| 02/26/2019 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,502.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | ||||||
| 09/24/2018 | Eli Lilly and Company | — | Food and Beverage | Cash or cash equivalent | $62.75 | General |
| 09/08/2018 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $230.00 | General |
| 09/08/2018 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $171.72 | General |
| 09/08/2018 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $162.49 | General |
| 09/06/2018 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $479.91 | General |
| 02/17/2018 | DUSA Pharmaceuticals, Inc. | Levulan Kerastick (aminolevulinic acid HCl) for Topical Solution, 20% (Drug), BLU-U Blue Light Photodynamic Therapy Illuminator Model 4170 | Food and Beverage | In-kind items and services | $26.33 | General |
| Category: Dermatology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | Eli Lilly and Company | $1,664 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 523 | 939 | $153,218 | $29,019 |
| 2022 | 11 | 575 | 980 | $144,887 | $29,254 |
| 2021 | 12 | 617 | 979 | $125,762 | $27,865 |
| 2020 | 13 | 544 | 817 | $100,001 | $20,668 |
Total Patients
2,259
Total Services
3,715
Medicare Billing
$106,806
Procedure Codes
51
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 149 | 215 | $42,424 | $10,406 | 24.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 72 | 109 | $32,637 | $7,745 | 23.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 66 | 96 | $18,912 | $3,554 | 18.8% |
| 17261 | Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | Office | 2023 | 14 | 20 | $8,748 | $1,260 | 14.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 19 | 19 | $5,668 | $1,192 | 21.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 46 | 58 | $18,007 | $1,155 | 6.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 15 | 20 | $6,815 | $908.01 | 13.3% |
| 99451 | Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | Office | 2023 | 28 | 28 | $2,520 | $816.48 | 32.4% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 11 | 13 | $4,915 | $477.26 | 9.7% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 55 | 301 | $6,151 | $469.20 | 7.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 14 | 16 | $1,946 | $433.65 | 22.3% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 15 | 24 | $3,715 | $423.84 | 11.4% |
| 99421 | Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | Office | 2023 | 19 | 20 | $760.00 | $178.33 | 23.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 163 | 201 | $35,778 | $9,623 | 26.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 81 | 109 | $28,354 | $7,338 | 25.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 87 | 108 | $19,829 | $3,900 | 19.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 22 | 22 | $7,876 | $2,010 | 25.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 36 | 41 | $12,855 | $1,841 | 14.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 26 | 26 | $5,608 | $1,456 | 26.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 50 | 62 | $17,588 | $1,088 | 6.2% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 13 | 33 | $4,857 | $591.32 | 12.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 68 | 347 | $6,384 | $560.37 | 8.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 18 | 20 | $1,872 | $507.85 | 27.1% |
| 11104 | Punch biopsy, first skin growth | Office | 2022 | 11 | 11 | $3,886 | $339.19 | 8.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 188 | 245 | $37,087 | $10,883 | 29.3% |
About Teri Greiling, MD, PHD
Teri Greiling, MD, PHD is a Dermatology healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2011. The National Provider Identifier (NPI) number assigned to this provider is 1609168913.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Teri Greiling, MD, PHD has received a total of $10,692 in payments from pharmaceutical and medical device companies, with $5,164 received in 2024. These payments were reported across 17 transactions from 9 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($5,125).
As a Medicare-enrolled provider, Greiling has provided services to 2,259 Medicare beneficiaries, totaling 3,715 services with total Medicare billing of $106,806. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Other Specialties Dermatology
- Location Portland, OR
- Active Since 05/04/2011
- Last Updated 08/22/2016
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1609168913
Products in Payments
- DUPIXENT (Biological) $5,125
- COSENTYX (Biological) $2,400
- Otezla (Drug) $136.87
- TREMFYA (Drug) $39.08
- TALTZ (Drug) $36.83
- OLUMIANT (Drug) $27.17
- Levulan Kerastick (aminolevulinic acid HCl) for Topical Solution, 20% (Drug) $26.33
- Tremfya (Drug) $13.35
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Portland
Andrew Blauvelt, Md, MD
Dermatology — Payments: $2.6M
Dermatology $2.6M
Eric Simpson, Md, MD
Dermatology — Payments: $2.2M
Dermatology $2.2M
Benjamin Ehst, M.d., Ph.d, M.D., PH.D
Dermatology — Payments: $1.5M
Dermatology $1.5M
Dr. Jason Hawkes, Md, Ms, MD, MS
Dermatology — Payments: $876,779
Dermatology $876,779
Dr. Omar Qutub, Md, MD
Dermatology — Payments: $73,858
Dermatology $73,858
Alex Ortega Loayza, Md, MD
Dermatology — Payments: $72,824
Dermatology $72,824